Yestar Healthcare Narrows Loss in 2023
Yestar Healthcare Holdings (HKG:2393) reported an attributable loss of 13.9 million yuan for the year ended Dec. 31, 2023, compared with a loss of 992.2 million yuan in the previous year, according to
巨星醫療控股:年度報告 2023
Yestar Healthcare Faces Second Arbitration Related to Trading Firm Acquisition
Yestar Healthcare Holdings (HKG:2393) received a notice of a second arbitration related to its acquisition of a 70% stake in Guangzhou Shengshiyuan Trading, according to a filing with the Hong Kong Ex
Superstar Healthcare Holdings (02393): Leung Chun-hung resigns as executive director
Superstar Medical Holdings (02393) announced that Leung Chun-hung undertakes other duties related to his future career and business development...
Superstar Medical Holdings (02393) announced annual results. Losses attributable to shareholders of 13.888 million yuan narrowed 98.6% year-on-year
According to the Zhitong Finance App, Superstar Medical Holdings (02393) announced its annual results for the year ended December 31, 2023. The group achieved continuous business revenue of 2,913 billion yuan (RMB, same below) during the period, an increase of 3.86% over the previous year; losses attributable to shareholders were 13.888 million yuan, a year-on-year decrease of 98.6%; and a basic loss of 0.6 points per share. According to the announcement, demand for the Group's in vitro diagnostic consumables increased in 2023, mainly due to a sharp rise in demand for cardiomyocardial products from patients with diseases caused by COVID-19 in the first quarter of 2023. Receipts from continuing operations in this segment
YESTAR HEALTH: ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2023
Superstar Medical Holdings (02393.HK) expects net loss of not more than 10 million yuan in fiscal year 2023
Gelonghui, March 15, 丨 Superstar Medical Holdings (02393.HK) announced that compared to the Group's audited net loss of approximately RMB 1.02 billion for the year ended December 31, 2022, the Group expects a sharp reduction in fiscal year 2023 and recorded a net loss of not more than RMB 10 million. The Group expects a sharp decrease in net losses in fiscal year 2023 mainly due to (i) a sharp reduction in impairment losses on goodwill and other intangible assets in fiscal year 2023; (ii) impairment losses on the return of some financial assets; and (iii) a sharp drop in financial costs.
YESTAR HEALTH: PROFIT WARNING
Superstar Healthcare Holdings (02393.HK) held a board meeting on March 27 to consider and approve the annual results
Glonghui, March 15, 丨 Superstar Healthcare Holdings (02393.HK) announced that the company will hold a board meeting on March 27, 2024 (Wednesday) to consider and approve (among other things) the annual results of the company and its subsidiaries for the year ended December 31, 2023, and to recommend payment of a final dividend (if any).
YESTAR HEALTH: DATE OF BOARD MEETING
Superstar Medical Holdings (02393) will redeem US$198 million 9.5% senior notes due in 2026
Superstar Medical Holdings (02393) announced that the company is known to be a trustee on March 13, 2024 (redemption...
Superstar Medical Holdings (02393) received the original written arbitration award and was required to pay the applicant a share transfer of $22.54 million
Zhitong Finance App News, Superstar Medical Holdings (02393) issued an announcement containing the latest news on the profit guarantee for the acquisition of 70% equity interest in Guangzhou Shengshiyuan Trading Co., Ltd., one of Sheng Shiyuan's sellers (holding 6% interest in Shengshiyuan) (the applicant) requested the company to acquire the relevant share capital rights related to 30% of Shengshiyuan's share capital interest at a cost of about RMB 225.42 million, and claimed from the company RMB 9.0899 million (provisional until May 10, 2023). The arbitral tribunal commenced in November 2023
Superstar Medical Holdings (02393): The proposed debt repayment plan has been approved by the required majority of the plan's creditors
According to the Zhitong Finance App, Superstar Healthcare Holdings (02393) announced that the planned creditors' meeting held at the office of Dejie Law Firm on the 31st floor of Jardine Building, 1 Connaught Place, Central, Hong Kong will begin at 8:02 p.m. on February 19, 2024, Hong Kong time. At the meeting, a total of 124 plan creditors participated in the planning meeting. Among them, 124 plan creditors voted in favor of the proposed debt repayment plan. As a result, the plan has been approved by the required majority of plan creditors. The plan will then be subject to court approval and approval. The company hereby announces that it will seek a court appointment in Cayman Islands Time2
Yestar Healthcare to Host Creditors Meeting for Debt Restructuring Scheme on Feb. 19
Yestar Healthcare Holdings (HKG:2393) provided an update on its offshore debt restructuring scheme, saying the Grand Court of the Cayman Islands has directed the firm to convene a meeting with the scheme creditors.
Yestar Healthcare Completes Disposal of Group of Companies; Shares Up 3%
Yestar Healthcare Holdings (HKG:2393) completed the disposal of a group of companies. The medical consumables and equipment company's subsidiary, Yestar Medical, sold 94.2% in each of Shanghai Emphasi
All prerequisites for the share transfer agreement of Superstar Medical Holdings (02393) have been fulfilled
According to the Zhitong Finance App, Superstar Medical Holdings (02393) issued an announcement on matters relating to the share transfer agreement, where the seller conditionally agreed to sell and the buyer conditionally agreed to acquire target shares at a cost of RMB 575 million. The Board of Directors is pleased to announce that all preconditions to the share transfer agreement have been fulfilled, and the completion was implemented on January 12, 2024 in accordance with the terms of the share transfer agreement. After completion, the company no longer holds any equity interest in the target company. As a result, the target company is no longer a subsidiary of the company and will no longer be consolidated in the Group's financial statements.
Superstar Medical Holdings (02393.HK): Completed the sale of shares of Shanghai Ambaida Investment and others
On January 12, Ge Longhui | Superstar Medical Holdings (02393.HK) announced that it plans to sell 94.2% of the equity interests of Shanghai Amberta Investment, Shanghai Construction and Storage Healthcare, Shanghai Superlink Trading, Shanghai Haole Industrial, and Shanghai Dingpei Industrial at a cost of RMB 575 million. All prerequisites for the share transfer agreement have been fulfilled, and completion was implemented on January 12, 2024 in accordance with the terms of the share transfer agreement. After completion, the company no longer holds any equity interest in the target company. As a result, the target company is no longer a subsidiary of the company and will no longer be consolidated in the Group's financial statements.
James Hartono sold 62.6775 million common shares of Superstar Healthcare Holdings (02393.HK) worth approximately HK$1,316,200
On January 2, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on January 2, 2023, James Hartono sold $62.6775 million common shares of $Superstar Medical Holdings (02393.HK) at an average price of HK$0.021 per share, worth approximately HK$1,316,200. After the sale, James Hartono's latest shareholding was 554 million shares, and the good position ratio dropped from 26.46% to 23.78%. Photo Source: Stock Exchange Equity Disclosure What is equity disclosure? According to the requirements of the Hong Kong Stock Exchange, major shareholders (holding
Changes in Hong Kong stocks 丨 Superstar Healthcare's resumption of trading soared by nearly 90%, and non-executive holdings were sold by brokerage firms before plummeting for 2 consecutive days
Glonghui, December 29 | Superstar Healthcare (2393.HK) was temporarily suspended after a sharp drop of 67% yesterday. It drew high after resuming trading this morning. At one point, it rose 88.46% to HK$0.049 in the intraday period. However, the transaction was weak. Up to now, it has only sold HK$7.79 million. The stock had previously plummeted for 2 consecutive trading days, falling 85%. The Group recently stated that non-executive director He Zhenfa's 64.14 million shares of the company held in two securities trading accounts subject to guaranteed financing were sold on the market, accounting for about 2.8% of the total issued share capital. Ho has confirmed that the sold shares are held as securities under margin financing arrangements
Superstar Medical Holdings (02393.HK) resumed trading this morning
On December 29, Gelonghui | Superstar Medical Holdings (02393.HK) announced that the company's shares will resume trading at 9:00 a.m. today (29/12/2023).
No Data